Respiree Secures Second FDA 510(k) Clearance, Expands Cardio-Respiratory Wearable to Home Use via 1Bio™ Connected Care Platform
Illustrative Image of Respiree's RS001 Wearable With its Connected Care 1Bio™ Platform
The RS001 is a chest-worn device that directly measures respiration and offers passive cardio-respiratory monitoring. Originally cleared for in-patient clinical use, the RS001's use in home settings marks a significant step toward more accessible and preventive healthcare. The device connects to a cellular hub, which enables data to be visualized in real time via the connected care 1Bio™ dashboard.
'Respiration is the most predictive vital sign for clinical deterioration, yet it remains underutilized – particularly outside hospital settings,' said Dr. Gurpreet Singh, CEO and Founder of Respiree. 'This FDA 510(k) extension allows healthcare systems to passively and accurately monitor leading indicators in the home, enabling earlier interventions and reducing the overall burden on healthcare infrastructure.'
The announcement follows Respiree's recent US$11.6 million Series A financing round, led by We Venture Capital and ClavystBio, which will accelerate development toward potential regulatory approvals and global market expansion. Respiree also announced plans to pursue additional FDA clearances for its proprietary AI software, aiming to integrate artificial intelligence models into the 1Bio™ platform for both inpatient and home-based care.
'These are exciting times for us,' added Dr. Singh. 'Our first 510(k) was for the wearable; this second one is for the platform. We are now focused on bringing our flagship AI models into the fold as a Software as a Medical Device (SaMD).'
About Respiree
Respiree™ is an AI/ML health tech company building state-of-the-art clinically-validated artificial intelligence (AI) for managing disease progression across healthcare's care continuum. The 1Bio™ platform by Respiree™ uses data from the EHR and its proprietary US-patented and FDA-cleared sensors to longitudinal measure and track disease progression. Respiree™ is now available in U.S., Australia and Asia-Pacific (APAC). Respiree™ is CE marked, has received regulatory clearances in Australia from the Therapeutics Goods Administration and has received the 510k clearance from the United States Food and Drug Administration (FDA). (www.respiree.com)
Media Enquiries
Evangeline FuAdministrative ManagerRespiree Pte LtdEmail: evangeline@respiree.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/aea7197c-89ac-4dbb-82b9-da85e7dd07f8Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
16 minutes ago
- Forbes
CDC: Childhood Vaccination Rates Fell Further In 2024-2025 School Year
Childhood vaccination rates dropped even further for the 2024-2025 school year down to the lower 92% range with a record number of exemptions from vaccinations among kindergarteners, according to new data from the U.S. Centers for Disease Control and Prevention. Meanwhile, this year the U.S. has already experiencing the most measles cases and outbreaks that it's had in years with 1,333 and 29, respectively. Gee, do you think these things are somehow connected in any way? Well, the likely answer rhymes with the word 'mess.' Childhood Vaccination Rates Have Fallen To The 92% Range 'A mess' can describe what used to be a tidy public health situation. The newest CDC data shows that measles, mumps, rubella vaccination coverage among kindergarteners continued a downward trend. Rates have dropped from 95.2% in the 2019-2020 school year down to 92.7% in the 2023-2024 school year and even further to 92.5% this past school year. Coverage numbers for other vaccines have been going the wrong direction as well. Rates for the diphtheria, tetanus, and acellular pertussis vaccine otherwise known as the DTaP vaccine have fallen from 94.9% in 2019-2020 to 92.3% in 2023-2024 to 92.1% this past school year. Over the same time periods. the percentage of kids who got two doses of the varicella vaccine went from 94.8% to 92.3% to 92.1%. And coverage for the polio vaccine has gone from 95% to 92.7% to 92.5%. All of this has corresponded to a rise in the number of parents seeking exemptions from vaccinations for their children, going from 2.5% in the 2020-2021 schools year to 3.3% in 2023-24 to 3.6% in 2024-25. The U.S. basically had an all-time record number of such exemptions last school year with around 138,000 children getting them for at least one vaccine. And this isn't an issue in just a few states painted a certain political color. The majority of states (36 of them) in the U.S. as well as the District of Columbia had increases in exemptions from the previous. In fact, 17 states saw exemption rates that went above 5%. And which state do you think had the highest rate of exemptions? It rhymes with 'I don't know.' Idaho had the highest rate at a whopping 15.4% 2025 Has Already Had 1,333 Confirmed Measles Cases, 29 Outbreaks Meanwhile, the U.S. continues to go back in time when it comes to the measles. Measles outbreaks were very common before the arrival of the measles vaccine in the 1960s. Then over time as vaccination coverage increased, the threat of measles decreased. Once measles vaccination rates stayed above the herd immunity threshold of 95% for years, measles became rarer and rarer. That was because with such a large percentage of the population vaccinated, the measles virus had trouble finding unprotected humans to infect and treat like a cheap motel to reproduce and spread further. Eventually, the measles virus was effectively gone baby gone from the U.S., which declared measles eliminated in 2000. How quickly people forget, though. Since 2000, persistent misinformation and disinformation about the measles vaccine have helped erode MMR vaccination rates. Over the past decade, I've been writing more and more about measles cases and outbreaks, like this one, in the U.S. mainly because more and more measles cases and outbreaks have been occurring. I've written about I wrote in Forbes in 2019 about how anti-vaxxers made that year's World Health Organization's list of top ten global health threats All of this brings us to this year, which has been a great year if you are the measles virus. Not so great for many humans. As of July 29, there's already been a total of 1,333 confirmed measles cases across 40 jurisdictions, according to CDC data. Try to find the states that are not among the following that have had reported measles cases: Alaska, Arkansas, Arizona, California, Colorado, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maryland, Michigan, Minnesota, Missouri, Montana, Nebraska, New Jersey, New Mexico, New York City, New York State, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington and Wyoming. Oh, and measles is really contagious. Like really, really contagious. Among unvaccinated people, one case can easily lead to 12 to 18 more cases. About 87% of all reported measles cases this year have been part of outbreaks. This year has also already had 29 reported outbreaks, up from 16 in all of 2024. Lack Of More Urgent Action Dropping vaccination rates and rising measles cases and outbreaks should be more than a canary in a coal mine for the U.S. It should be a freaking elephant. We've essentially allowed a problem that was taken care of to return and potentially make America measle-ly again. Not only that. With other vaccination rates declining as well, we could see resurgences of other infectious disease as well, including polio. Things could be reversed if prompt actions are taken to get vaccination rates back up again before the different nasty microbes can spread too far in the U.S. population. But there doesn't seem to be an organized effort at the federal level to address these worsening problems. In fact, there are disturbing trends in the opposite direction such as the layoffs of personnel who were dedicated to help control infectious diseases, claims being made about vaccines that are unsupported by scientific evidence and cuts in funding for scientific research and public health efforts. The CDC website still has language about vaccination being simply a personal choice. But that simply is not the case. Since the percentage of people vaccinated affects the spread of viruses and other microbes, each person's decision to get vaccinated affects everyone else's risk of getting the disease. Therefore, having people around you not vaccinated against say the measles raises your risk of your risk of getting the measles, even if you yourself are already vaccinated against the measles. In other words, childhood vaccinations are not simply child's play.
Forbes
16 minutes ago
- Forbes
How Google's Pixel 10 Pro Can Defeat Apple's New iPhone 17
Google will launch the new Pixel 10 and Pixel 10 Pro smartphones this month, and the new family of Pixels has an opportunity within reach that no other Pixel has had so far... the chance to take on and claim victory against Apple's iPhone. The latter will launch early in September and will no doubt be seen as 'the best iPhone ever' by the faithful. The Pixel 10 family is not going after that market; they belong to Apple in much the same way that Google has a tranche of users dedicated to the Pixel brand. Sales to these loyal crowds are locked in. The challenge is the group in the middle, the group that will happily swap manufacturers, proficient in living in multiple clouds, and always looking for the best balance. The Pixel 10 family, especially the Pixel 10 Pro, will speak to all of that market. Pixel 10 Pro Wins The Price Discussion First up is the price. Google appears to be keeping the prices of the Pixel 10, Pixel 10 Pro, and Pixel 10 Pro XL in line with the Pixel 9 family launched last year. On the other hand, Apple is set to add a $50 premium across the board for the iPhone 17 handsets. Apple is mitigating this by increasing the base level of storage on these entry-level models, so a like-for-like comparison with the second-tier models of the iPhone 16 will show an effective $50 saving year-on-year. That needs a close reading of the specifications to become clear. A quick comparison online or in-store of the prices will show (as much like-for-like as you can get between Android and iOS) that the Pixel is the more cost-effective option. Pixel 10 Pro Wins This Round Of AI It can't have escaped anyone's notice that artificial intelligence is the latest buzzword in computing. This isn't restricted to mobile; everywhere you turn, you can see AI being used in countless ways. The smartphone is the key computing device for many, and the AI revolution is incredibly visible on the smartphone. At least on Android smartphones. Apple's efforts in artificial intelligence have fallen short of the publicly announced goals at its Worldwide Developer Conference in June 2024. Features that were going to debut on the iPhone 16, then would be coming by the end of the year, may turn up ahead of the iPhone 17 launch. That delay, of more than a year, hands Google a visible win for those expecting modern artificial intelligence on their smartphone. Pixel 10 Pro Has More To Show In 2025 That's just the state of play of AI right now. When the Pixel 10 smartphones are launched, they will have all the added AI benefits from Android 16, as well as the new tools and updates in Google's first-party apps. AI will continue to be one of the buzzwords of 2025. Google will have demonstrated its lead and then extended it as consumers get ready to buy their new smartphones. Apple's AI efforts are still trying to match the promises of June 2024. Those who have purchased the iPhone 16 and iPhone 16 Pro smartphones Add to that the leap forward that Google will make with the launch of Android 16 on the Pixel 10 phones, as well as the new AI features in Google's first-party apps, and you can see how Pixel will have an AI advantage with consumers. Apple's AI promises from WWDC 2025 are less than grand. Advantage Pixel 10 Pro A better price on retail shelves, a better acknowledgement of artificial intelligence, and more new features that will extend its lead in mobile AI. The Pixel 10 and Pixel 10 Pro smartphones have more advantages over the iPhone than the Pixel range has had to date. Now read the latest Pixel 10 Pro headlines in Forbes' weekly Android news digest...
Yahoo
44 minutes ago
- Yahoo
David Sacks says the doomsday scenario of AI wiping out jobs is 'overhyped'
Artificial general intelligence hinges on the idea that AI can reach human levels of reasoning. White House AI and crypto czar David Sacks says we're not quite there yet. The investor said AI still needs human input in order to provide "meaningful business value." David Sacks, the White House AI and crypto czar, is throwing cold water on the AGI hype train. AI companies are racing to achieve AGI, or artificial general intelligence, commonly considered a form of AI that can reach human levels of reasoning. The continued advancement of AI has led some to believe that the technology will lead to a large-scale wipeout of jobs or even worse outcomes, like human extinction. Sacks, a tech investor who has supported major companies such as Airbnb, Facebook, and Uber, wrote in an X post on Saturday that AI hasn't progressed as quickly as many have predicted — specifically, the idea that AI will "self-improve" and rapidly achieve "godlike superintelligence" has been blown out of proportion. "None of this is to gainsay the progress. We are seeing strong improvement in quality, usability, and price/performance across the top model companies. This is the stuff of great engineering and should be celebrated," Sacks wrote in his post. "It's just not the stuff of apocalyptic pronouncements. Oppenheimer has left the building." One of the doomsday scenarios Sacks rejected in his post is the fear that AI will lead to massive job losses. The investor said that's yet to pan out since AI relies on a lot of human input for prompts and for verification. "This means that apocalyptic predictions of job loss are as overhyped as AGI itself," he said. "Instead, the truism that 'you're not going to lose your job to AI but to someone who uses AI better than you' is holding up well." Sacks isn't the only AGI naysayer. Google Brain's cofounder Andrew Ng said at a June Y Combinator talk that "AGI has been overhyped" and that "there'll be a lot of things that humans can do that AI cannot." Google CEO Sundar Pichai said in a Lex Fridman podcast that he likes to use the term AJI, or "artificial jagged intelligence," to describe the current phase of AI — one that is remarkably intelligent but can still make basic mistakes. Sacks did not respond to a request for comment. Read the original article on Business Insider
